← FDA DRUG APPROVALS

FDA ANDA · ANDA071426

VINCASAR PFS

Sponsor: TEVA PARENTERAL

APPLICATION
ANDA071426
TYPE
ANDA
ORIGINAL APPROVAL
1987-07-17
LATEST ACTION
1999-05-17
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

VINCASAR PFSDiscontinued
VINCRISTINE SULFATE 1MG/ML · INJECTABLE · INJECTION

Approval history

1999-05-17Labeling · Supplement 23AP
1995-11-07Labeling · Supplement 22AP
1993-07-08Manufacturing (CMC) · Supplement 16AP
1993-07-08Labeling · Supplement 17AP
1993-03-05Labeling · Supplement 21AP
1992-11-13Labeling · Supplement 20AP
1992-09-17Labeling · Supplement 19AP
1992-08-21Manufacturing (CMC) · Supplement 18AP
1991-11-25Labeling · Supplement 13AP
1991-03-04Manufacturing (CMC) · Supplement 6AP
1991-01-29Labeling · Supplement 12AP
1989-02-21Labeling · Supplement 4AP
1989-02-21Manufacturing (CMC) · Supplement 2AP
1989-02-21Manufacturing (CMC) · Supplement 9AP
1988-12-23Labeling · Supplement 10AP
1988-07-27Manufacturing (CMC) · Supplement 8AP
1988-07-27Manufacturing (CMC) · Supplement 7AP
1988-03-24Labeling · Supplement 5AP
1987-07-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →